stockrowAmgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Revenue growth
Amgen Inc.'s revenue growth over the twelve months to 30 September 2026 was 8.15%, down 1.8 percentage points from fiscal 2025 (9.95%). Over the past ten years it has ranged from −1.62% (fiscal 2019) to 18.6% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 6.72% and in line with the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 9.95% | (8.62) |
| FY2024 | 18.6% | 11.48 |
| FY2023 | 7.09% | 5.77 |
| FY2022 | 1.32% | (0.86) |
| FY2021 | 2.18% | (6.65) |
| FY2020 | 8.83% | 10.45 |
| FY2019 | −1.62% | (5.55) |
| FY2018 | 3.93% | 4.55 |
| FY2017 | −0.62% | (6.76) |
| FY2016 | 6.14% | (1.83) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 8.45% | (1.08) |
| Jun 2026 | 9.53% | 3.77 |
| Mar 2026 | 5.76% | (2.82) |
| Dec 2025 | 8.58% | (3.82) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NVO Novo Nordisk A/S compare | 13.2% |
| ABBV AbbVie Inc. compare | 10.7% |
| AMGN Amgen Inc. | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| MRK Merck & Co., Inc. compare | 4.89% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement